Related Experiment Video
Updated: Mar 30, 2026
04:01
Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma
Published on: September 15, 2023
1.7K
[BRAF-STATUS OF PAPILLARY THYROID CARCINOMAS AND STRATEGY OF SURGICAL TREATMENT]
Klinichna Khirurhiia
|November 3, 2015
Summary
Detecting the BRAF V600E mutation in thyroid nodules may help preoperatively diagnose papillary carcinoma (PC). This molecular marker was exclusively found in PC patients, aiding in preoperative diagnosis.
Area of Science:
- Oncology
- Molecular Diagnostics
- Endocrinology
Background:
- Papillary carcinoma (PC) is the most common type of thyroid cancer.
- Accurate preoperative diagnosis is crucial for effective patient management.
- Identifying specific molecular markers can improve diagnostic accuracy.
Purpose of the Study:
- To investigate the presence of the BRAF V600E mutation in focal thyroid lesions.
- To evaluate the BRAF V600E mutation as a potential preoperative diagnostic marker for thyroid papillary carcinoma (PC).
Main Methods:
- Molecular genetic testing was performed on fine-needle aspiration (FNA) samples from 26 patients.
- Samples were analyzed for the BRAF V600E mutation preoperatively.
- Morphological investigations were used to verify the final diagnosis.
Main Results:
- The BRAF V600E mutation was detected exclusively in patients diagnosed with thyroid papillary carcinoma (PC).
- No BRAF V600E mutations were found in non-PC thyroid lesions.
Conclusions:
- The BRAF V600E mutation serves as a specific marker for preoperative diagnosis of thyroid papillary carcinoma (PC).
- Integrating molecular testing for BRAF V600E can enhance the preoperative diagnostic accuracy of PC.
